SCAI 2026 Sirolimus-Eluting Balloons in Coronary PCI: Key Insights from Recent Evidence-Where Are We Now: DCB and DEB Technologies, Current Data, Trials Indications, and Clinical Guidance, Dr. Waksman

Where Are We Now: DCB and DEB Technologies, Current Data, Trials Indications, and Clinical Guidance, Dr. Waksman

Video Transcription

Video Summary

The speaker argues that drug-coated balloons (DCB) are transforming PCI and are supported by growing global data. He reviews evidence for in-stent restenosis, de novo lesions, small vessels, and bifurcations, noting that DCBs often appear non-inferior to DES, though results vary by lesion type and study. He compares paclitaxel- and sirolimus-coated technologies, finding no clear overall winner yet. He emphasizes that the U.S. is behind other regions but more trials are underway. Overall, he says this is the beginning of a new era in coronary intervention.

Asset Caption

closed captions are computer-generated

Keywords

drug-coated balloons

PCI

in-stent restenosis

de novo lesions

coronary intervention